 Scot Sedlacek
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2019 | 2456 | 0.910 |
Why?
| | Survivors | 5 | 2015 | 520 | 0.430 |
Why?
| | Diet, Reducing | 2 | 2012 | 91 | 0.350 |
Why?
| | Dietary Carbohydrates | 2 | 2012 | 151 | 0.340 |
Why?
| | Dietary Fats | 2 | 2012 | 315 | 0.310 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2017 | 1958 | 0.310 |
Why?
| | Biomarkers, Tumor | 2 | 2015 | 1322 | 0.220 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2011 | 142 | 0.210 |
Why?
| | Fruit | 5 | 2006 | 152 | 0.210 |
Why?
| | Vegetables | 5 | 2006 | 170 | 0.210 |
Why?
| | Mitomycins | 2 | 1993 | 6 | 0.180 |
Why?
| | Vinblastine | 2 | 1993 | 75 | 0.180 |
Why?
| | Leptin | 2 | 2015 | 245 | 0.180 |
Why?
| | Adiponectin | 2 | 2015 | 244 | 0.170 |
Why?
| | Weight Loss | 3 | 2015 | 837 | 0.160 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1465 | 0.160 |
Why?
| | Lymphatic Metastasis | 4 | 2010 | 334 | 0.150 |
Why?
| | Mouthwashes | 1 | 2019 | 13 | 0.150 |
Why?
| | Stomatitis | 1 | 2019 | 16 | 0.150 |
Why?
| | Prednisolone | 1 | 2019 | 66 | 0.140 |
Why?
| | Everolimus | 1 | 2019 | 111 | 0.140 |
Why?
| | Carcinoma, Lobular | 1 | 1999 | 56 | 0.140 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 1999 | 88 | 0.140 |
Why?
| | Tamoxifen | 5 | 2009 | 217 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2010 | 931 | 0.130 |
Why?
| | Epothilones | 1 | 2017 | 2 | 0.130 |
Why?
| | Lymph Nodes | 2 | 2005 | 502 | 0.130 |
Why?
| | Carboplatin | 1 | 2017 | 160 | 0.130 |
Why?
| | Carotenoids | 4 | 2006 | 48 | 0.120 |
Why?
| | Lipid Peroxidation | 4 | 2006 | 160 | 0.120 |
Why?
| | Hydrocortisone | 1 | 2019 | 304 | 0.120 |
Why?
| | Middle Aged | 25 | 2019 | 35928 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 451 | 0.110 |
Why?
| | Capecitabine | 1 | 2015 | 57 | 0.110 |
Why?
| | Postmenopause | 3 | 2015 | 391 | 0.110 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 105 | 0.110 |
Why?
| | Diet | 4 | 2006 | 1275 | 0.110 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2017 | 216 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2015 | 1141 | 0.100 |
Why?
| | Dinoprost | 4 | 2006 | 49 | 0.100 |
Why?
| | Gene Amplification | 1 | 2013 | 121 | 0.100 |
Why?
| | Oxidative Stress | 3 | 2005 | 1339 | 0.090 |
Why?
| | Analysis of Variance | 3 | 2011 | 1311 | 0.090 |
Why?
| | Female | 32 | 2019 | 78376 | 0.090 |
Why?
| | Counseling | 2 | 2010 | 408 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2015 | 421 | 0.090 |
Why?
| | Receptors, Progesterone | 3 | 2017 | 356 | 0.090 |
Why?
| | Telephone | 2 | 2010 | 175 | 0.080 |
Why?
| | Adipose Tissue | 2 | 2015 | 653 | 0.080 |
Why?
| | Body Weight | 1 | 2015 | 978 | 0.080 |
Why?
| | Follow-Up Studies | 8 | 2015 | 5417 | 0.080 |
Why?
| | Overweight | 1 | 2015 | 609 | 0.080 |
Why?
| | Weight Reduction Programs | 1 | 2011 | 137 | 0.080 |
Why?
| | Mammaplasty | 1 | 2011 | 104 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2011 | 417 | 0.070 |
Why?
| | Mastectomy, Segmental | 2 | 2002 | 108 | 0.070 |
Why?
| | Aged | 15 | 2019 | 25947 | 0.070 |
Why?
| | Megestrol | 1 | 1988 | 2 | 0.070 |
Why?
| | Adult | 18 | 2019 | 40506 | 0.070 |
Why?
| | Estrogens | 1 | 2011 | 380 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 621 | 0.070 |
Why?
| | Hot Flashes | 1 | 2009 | 88 | 0.070 |
Why?
| | Obesity | 2 | 2012 | 3082 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2009 | 141 | 0.070 |
Why?
| | Estrogen Replacement Therapy | 1 | 2009 | 144 | 0.070 |
Why?
| | Humans | 32 | 2019 | 144957 | 0.070 |
Why?
| | Progestins | 2 | 1985 | 87 | 0.060 |
Why?
| | Aged, 80 and over | 7 | 2019 | 8279 | 0.060 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2009 | 194 | 0.060 |
Why?
| | Homeostasis | 1 | 2011 | 640 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2011 | 780 | 0.060 |
Why?
| | Deoxyguanosine | 3 | 2005 | 25 | 0.060 |
Why?
| | Lipids | 1 | 2012 | 710 | 0.060 |
Why?
| | Prognosis | 5 | 2015 | 4293 | 0.060 |
Why?
| | Patient Education as Topic | 2 | 2010 | 780 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1217 | 0.060 |
Why?
| | Biomarkers | 6 | 2015 | 4275 | 0.060 |
Why?
| | Glucose | 1 | 2011 | 1049 | 0.060 |
Why?
| | Cyclophosphamide | 3 | 2013 | 266 | 0.060 |
Why?
| | Diet, Fat-Restricted | 2 | 2015 | 79 | 0.060 |
Why?
| | Algorithms | 2 | 2011 | 1839 | 0.050 |
Why?
| | Taxoids | 2 | 2015 | 116 | 0.050 |
Why?
| | Receptors, Estrogen | 4 | 2017 | 457 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 966 | 0.050 |
Why?
| | Survival Rate | 4 | 2013 | 2092 | 0.050 |
Why?
| | Treatment Outcome | 7 | 2015 | 11695 | 0.050 |
Why?
| | Antioxidants | 1 | 2005 | 549 | 0.040 |
Why?
| | Blood Glucose | 1 | 2012 | 2330 | 0.040 |
Why?
| | Body Mass Index | 3 | 2015 | 2438 | 0.040 |
Why?
| | Lutein | 1 | 2000 | 16 | 0.040 |
Why?
| | Neoplasm Metastasis | 3 | 1993 | 695 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 1995 | 1268 | 0.040 |
Why?
| | Axilla | 1 | 1999 | 51 | 0.040 |
Why?
| | Prospective Studies | 3 | 2019 | 7997 | 0.040 |
Why?
| | Lymphocytes | 3 | 2006 | 382 | 0.030 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 21 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 1999 | 509 | 0.030 |
Why?
| | DNA Damage | 1 | 2000 | 430 | 0.030 |
Why?
| | Family | 2 | 1999 | 679 | 0.030 |
Why?
| | Paclitaxel | 2 | 2010 | 256 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 1996 | 29 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 423 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2017 | 133 | 0.030 |
Why?
| | Time Factors | 3 | 2015 | 7183 | 0.030 |
Why?
| | Estrogen Antagonists | 1 | 1995 | 48 | 0.030 |
Why?
| | Doxorubicin | 2 | 2010 | 397 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 475 | 0.030 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2015 | 37 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 1999 | 1540 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 222 | 0.030 |
Why?
| | Private Practice | 1 | 1995 | 19 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2015 | 117 | 0.030 |
Why?
| | Hospitals, Public | 1 | 1995 | 30 | 0.030 |
Why?
| | Fatigue | 1 | 2017 | 366 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 139 | 0.030 |
Why?
| | Anthropometry | 1 | 2015 | 200 | 0.030 |
Why?
| | Hospitals, University | 1 | 1995 | 176 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 309 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2013 | 1054 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1990 | 0.030 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2013 | 36 | 0.020 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2013 | 47 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2002 | 2365 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 1996 | 612 | 0.020 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 1993 | 15 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 1996 | 444 | 0.020 |
Why?
| | Trastuzumab | 1 | 2013 | 118 | 0.020 |
Why?
| | Vasoconstrictor Agents | 2 | 2006 | 144 | 0.020 |
Why?
| | Research Design | 1 | 1999 | 1137 | 0.020 |
Why?
| | Health Promotion | 1 | 1999 | 774 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 1999 | 1721 | 0.020 |
Why?
| | Survival Analysis | 1 | 1995 | 1385 | 0.020 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 272 | 0.020 |
Why?
| | Oxidation-Reduction | 2 | 2005 | 1087 | 0.020 |
Why?
| | Body Composition | 1 | 2015 | 706 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 1999 | 848 | 0.020 |
Why?
| | Feasibility Studies | 2 | 2009 | 1095 | 0.020 |
Why?
| | Mass Screening | 1 | 1999 | 1348 | 0.020 |
Why?
| | Mutation | 2 | 2002 | 4099 | 0.020 |
Why?
| | Tattooing | 1 | 2009 | 12 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 1003 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2015 | 685 | 0.020 |
Why?
| | Breast Diseases | 1 | 2008 | 22 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2009 | 289 | 0.020 |
Why?
| | Thoracic Wall | 1 | 2008 | 21 | 0.020 |
Why?
| | Esthetics | 1 | 2008 | 41 | 0.020 |
Why?
| | Megestrol Acetate | 1 | 1988 | 3 | 0.020 |
Why?
| | Gold | 1 | 2009 | 116 | 0.020 |
Why?
| | Program Development | 1 | 2010 | 370 | 0.020 |
Why?
| | Transcription Factors | 1 | 1996 | 1742 | 0.020 |
Why?
| | Mammography | 1 | 2009 | 166 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2008 | 149 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2009 | 160 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2197 | 0.020 |
Why?
| | Pelvic Exenteration | 1 | 1987 | 12 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1988 | 143 | 0.020 |
Why?
| | Tumor Burden | 1 | 2008 | 322 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 988 | 0.020 |
Why?
| | Anus Neoplasms | 1 | 1987 | 32 | 0.020 |
Why?
| | Sacrum | 1 | 1987 | 78 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 949 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1500 | 0.010 |
Why?
| | Social Support | 1 | 2010 | 652 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1987 | 158 | 0.010 |
Why?
| | Risk Factors | 2 | 2010 | 10792 | 0.010 |
Why?
| | Adaptation, Psychological | 1 | 2010 | 717 | 0.010 |
Why?
| | Weight Gain | 1 | 2009 | 559 | 0.010 |
Why?
| | Young Adult | 2 | 2013 | 14126 | 0.010 |
Why?
| | Menopause | 1 | 1988 | 320 | 0.010 |
Why?
| | DNA | 2 | 2005 | 1464 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2005 | 769 | 0.010 |
Why?
| | Ovarian Neoplasms | 2 | 2002 | 586 | 0.010 |
Why?
| | Pain | 1 | 2008 | 782 | 0.010 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 33 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 45 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1987 | 642 | 0.010 |
Why?
| | Probability | 1 | 2002 | 312 | 0.010 |
Why?
| | Patient Compliance | 1 | 2005 | 589 | 0.010 |
Why?
| | Colorado | 1 | 2010 | 4564 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 1984 | 1054 | 0.010 |
Why?
| | Medical History Taking | 1 | 1999 | 117 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5965 | 0.010 |
Why?
| | Quality of Life | 1 | 2010 | 3192 | 0.010 |
Why?
| | Pedigree | 1 | 1999 | 514 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1999 | 598 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 851 | 0.010 |
Why?
| | Retrospective Studies | 1 | 1995 | 17101 | 0.010 |
Why?
| | Informed Consent | 1 | 1999 | 198 | 0.010 |
Why?
| | United States | 2 | 1999 | 15988 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 1996 | 67 | 0.010 |
Why?
| | Genetic Markers | 1 | 1996 | 331 | 0.010 |
Why?
| | DNA Primers | 1 | 1996 | 512 | 0.010 |
Why?
| | Lung | 1 | 2008 | 4109 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1996 | 409 | 0.010 |
Why?
| | Exons | 1 | 1996 | 358 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 719 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1996 | 348 | 0.010 |
Why?
| | Treatment Refusal | 1 | 1995 | 98 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 22453 | 0.010 |
Why?
| | Diagnostic Errors | 1 | 1995 | 175 | 0.010 |
Why?
| | Registries | 1 | 2002 | 2385 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2191 | 0.010 |
Why?
| | Health Services Research | 1 | 1995 | 396 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1996 | 2931 | 0.010 |
Why?
| | Quality of Health Care | 1 | 1995 | 693 | 0.000 |
Why?
| | Health Personnel | 1 | 1995 | 748 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 6053 | 0.000 |
Why?
| | Chromatography, DEAE-Cellulose | 1 | 1985 | 12 | 0.000 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 1985 | 25 | 0.000 |
Why?
| | Affinity Labels | 1 | 1985 | 25 | 0.000 |
Why?
| | Estrenes | 1 | 1985 | 17 | 0.000 |
Why?
| | Oviducts | 1 | 1985 | 16 | 0.000 |
Why?
| | Mifepristone | 1 | 1985 | 64 | 0.000 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 1985 | 41 | 0.000 |
Why?
| | Receptor, Insulin | 1 | 1985 | 94 | 0.000 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1985 | 70 | 0.000 |
Why?
| | Molecular Weight | 1 | 1985 | 327 | 0.000 |
Why?
| | Chickens | 1 | 1985 | 191 | 0.000 |
Why?
| | Receptors, Glucocorticoid | 1 | 1985 | 138 | 0.000 |
Why?
| | Male | 3 | 1999 | 72406 | 0.000 |
Why?
| | Lipid Metabolism | 1 | 1985 | 528 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1985 | 1524 | 0.000 |
Why?
| | Cells, Cultured | 1 | 1985 | 4155 | 0.000 |
Why?
| | Rats | 1 | 1985 | 5614 | 0.000 |
Why?
| | Animals | 1 | 1985 | 38109 | 0.000 |
Why?
|
|
Sedlacek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|